资料发布时间:2018-10-30 14:50:00 最后更新时间: 2021-06-09 15:17:08
【药品简介】 威罗菲尼,是一种激酶抑制剂。通过抑制BRAF(丝氨酸-苏氨酸激酶),阻止缺乏细胞因子的细胞增殖,从而起到抗肿瘤效应。
【适应症状】 威罗菲尼,威罗菲尼是一种激酶抑制剂,威罗菲尼适用于有不可切除或转移黑色素瘤,且用FDA-批准的检验检测BRAFV600E突变患者的治疗。
【 药品别名 】 威罗菲尼 Vemurafenib
印度威罗菲尼(威罗菲尼 Vemurafenib)价格,正品图片,治疗黑色素瘤药物, 购买威罗菲尼请到印度药房官方网站进行购买 【印度药房大全目录】
【 市场参考价格 】 ¥3720.00~4000.00
播放/暂停
产品描述 |
Vemurafenib (PLX4032) is a novel and potent B-Raf (V600E) inhibitor (IC50: 31 nM). |
靶点活性 |
ACK1,19 nM (cell free) BLK,547nM B-Raf,100nM B-Raf (V600E),31 nM (cell free) BRK,213nM C-Raf,48nM CSK,2.339μM FGR,63nM FRK (PTK5),1.884μM Lck,183nM Lyn B,599nM MAP4K5 (KHS1),51nM MNK2,1.717μM NEK11,317nM Src,2.389μM SRMS,18 nM (cell free) WNK3,877nM Yes1,604nM c-Raf-1,48 nM (cell free) |
实验溶液 |
30% PEG400+0.5% Tween80+5% propylene glycol: 5 mg/mL |
体外活性 |
Vemurafenib (PLX4032, RG7204) displays similar potency for B-RAFV600E (31nM) and c-RAF-1 (48nM) and selectivity against many other kinases, including wild type B-RAF (100nM) [1]. In 17 melanoma cell lines, RG7204 was a potent inhibitor of proliferation in those expressing BRAFV600E but not BRAFWT. RG7204 also potently inhibited proliferation of melanoma cell lines expressing other codons 600 BRAF mutations (V600D, V600K, and V600R) [2]. Melanoma cells were more sensitive to PLX4032 than CRC cells. The inhibition of EGFR does not significantly affect the proliferation of EGFR in WiDr cells. In contrast, suppression of EGFR in combination with PLX4032 caused a marked inhibition of proliferation in WiDr cells [3]. |
体内活性 |
In BRAFV600E-mutant xenograft, PLX4032 (6 or 8 mg/kg) demonstrated dose-dependent inhibition of tumor growth, with higher exposures resulting in tumor regression [1]. In mice bearing Colo829 tumor xenografts, RG7204 at 100 mg/kg bid for 21 days showed greatly improved antitumor activity at the end of the study on day 38 after the tumor cell implant. There was complete tumor regression in all 10 mice treated with RG7204 by the end of the study [2]. In the dose-escalation cohort, among the 16 patients with melanoma whose tumors carried the V600E BRAF mutation and who were receiving 240 mg or more of PLX4032 twice daily, 10 had a partial response and 1 had a complete response [4]. |
激酶实验 |
Expression and purification of B-RAF, structure determination, and protein kinase activity measurements were carried out as previously described. To obtain co-crystals of B-RAFV600E with PLX4032, the protein solution was initially mixed with the compound dissolved in DMSO at a final compound concentration of 1 mM. This complex was co-crystallized by a sitting drop vapor diffusion experiment in which equal volumes of complex (at 10 mg/ml concentration) and reservoir solution (100mM BisTris at pH 6.0, 12.5% 2,5-hexanediol, and 12% PEG3350) were mixed and allowed to equilibrate against the reservoir at 4°C. The crystal was soaked in cryosolvent, followed by flash-freezing in liquid nitrogen. The data were collected at Beamline ALS831 with the wavelength of 1.11?. The Ramachandran plot from the refined structure shows that 94%, 5.6% and 0.4% residues are in the most favored, additional allowed and generously allowed regions, respectively. A summary of the crystallography statistics is included in Supplementary Table 3. COLO205 tumor xenograft studies (Molecular Imaging Research, Ann Arbor, MI) were carried out as previously described either using a conventional formulation (5%DMSO, 1% methylcellulose) or using the MBP formulation [1]. |
细胞实验 |
Cellular proliferation was evaluated by MTT assay. Briefly, cells were plated in 96-well microtiter plates at a density of 1,000 to 5,000 cells per well in a volume of 180 μL. For the assay, RG7204 was prepared at 10 times the final assay concentration in media containing 1% DMSO. Twenty-four hours after cell plating, 20 μL of the appropriate dilution were added to plates in duplicate. The plates were assayed for proliferation 6 days after the cells were plated according to the procedure originally described by Mosmann [2]. 细胞系: MALME-3M, Colo829, Colo38, A375, SK-MEL28, and A2058 cells |
动物实验 |
All animal procedures were approved by the Ethical Commission of the Institute for Cancer Research and Treatment and by the Italian Ministry of Health. WiDr cells were injected subcutaneously into the right posterior flanks of 7-week-old immunodeficient NODSCID female mice (6 mice per group). Tumour formation was monitored twice a week, and tumour volume based on caliper measurements was calculated by the modified ellipsoidal formula: tumour volume = 1/2 length × width. When tumours reached a volume of approximately 200–250 mm^3, mice were randomly assigned to treatment with vehicle or drug(s) [3]. 动物模型:Mice (athymic nude) xenograft models of LOX, Colo829, and A375 cells |
化学信息
分子量 |
489.92 |
分子式 |
C23H18ClF2N3O3S |
CAS |
918504-65-1 |
溶解度 |
DMSO: 90 mg/mL (183.7 mM) Ethanol: <1 mg/mL Water: <1 mg/mL ( < 1 mg/ml refers to the product slightly soluble or insoluble ) |
储存条件 |
store at -80°C |
备注 |
For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. |
配制溶液
1 mg | 5 mg | 10 mg | |
1 mM | 2.041 ml | 10.206 ml | 20.411 ml |
5 mM | 0.408 ml | 2.041 ml | 4.082 ml |
10 mM | 0.204 ml | 1.021 ml | 2.041 ml |
50 mM | 0.041 ml | 0.204 ml | 0.408 ml |
参考文献
在一项关于达拉非尼/曲美替尼治疗黑色素瘤的临床研究中,证明了达拉非尼/曲美替尼与黑色素瘤生存期之间的关系。依照该阶段研究......
黑色素瘤本身是一种非常危险的肿瘤。如果你想最大限度地提高患者的生存率,唯一能做的就是尽快做出诊断。我国皮肤恶性肿瘤的发病......
达拉非尼治疗效果怎么样国内患者恐怕不是很了解,因为达拉非尼至今仍未在我国上市,那达拉非尼的疗效怎么样呢?...
曲美替尼对黑色素瘤有什么作用?曲美替尼是治疗黑色素瘤的一类推荐药物,在世界范围内都是医患认可的药物。...
作为一种针对黑色素瘤的癌症靶向药物,威罗菲尼要求患者在用药过程中要小心。如果威罗菲尼使用不当,不仅会对我们的黑色素瘤治疗......
黑色素瘤又称恶性黑色素瘤多见于30岁以上的成年人,多发于皮肤以足底、外阴、肛门周围。...
根据病灶的浸润深度、有没有溃疡或者淋巴结转移的情况等,这些危险因素一般将术后的患者分为四类...
靶向治疗是一种只针对肿瘤细胞的治疗,不良反应小。...
Pharmacy Catalogue
【代购】【有实体店】【在线客服懂中文】
代购+直邮,印度抗癌药跨境医药电商直邮服务,让肿瘤患者能够有更好的选择,平台提供印度就医,印度易瑞沙,吉三代,吉二代,索......
【禁止中国访问 】【印度连锁】【品牌实力】
MedPlus是印度第二大药房连锁店。它经营1555家商店,其中1317家为公司所有,159家为特许经营公司,43家为医......
【药品种类丰富 】【渠道正规】【价格较高】
Wellness Forever是一家生活方式零售药房连锁店,致力于为印度本土客户提供全面的健康服务。目前总收入约为62......
【visa/万事达】 【全球可邮 】【纯线上销售】【可开处方】
Netmeds.com致力于开发印度本土市场,已成为印度领先的在线药店。Netmeds.com通过其全天候在线门户和移动......